ArticlePPAR research2008
Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies.
Article in PPAR research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 48 citations in OpenAlex.
- Insulin resistance induced by obesity: Mechanisms, metabolic implications and therapeutic approaches.Molecular biology reports · 2026Review
- Daily Intraperitoneal Administration of Rosiglitazone Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia.Pharmaceutics · 2022Article
- PFAS and Potential Adverse Effects on Bone and Adipose Tissue Through Interactions With PPARγ.Endocrinology · 2021Review
- DNA methylation in adipocytes from visceral and subcutaneous adipose tissue influences insulin-signaling gene expression in obese individuals.International journal of obesity (2005) · 2021Article
- PPARs and Angiogenesis-Implications in Pathology.International journal of molecular sciences · 2020Review
- Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease.Molecules (Basel, Switzerland) · 2020Review
- Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study.Cardiovascular diabetology · 2020Observational
- Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case-control study.Cardiovascular diabetology · 2019Article
- High-Throughput Screening of Lipidomic Adaptations in Cultured Cells.Biomolecules · 2019Article
- Article
- All-trans retinoic acid increases the expression of oxidative myosin heavy chain through the PPARδ pathway in bovine muscle cells derived from satellite cells.Journal of animal science · 2018Article
- Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs.International journal of medicinal chemistry · 2017Review
- Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives.International journal of molecular sciences · 2016Review
- Expression profiling analysis: Uncoupling protein 2 deficiency improves hepatic glucose, lipid profiles and insulin sensitivity in high-fat diet-fed mice by modulating expression of genes in peroxisome proliferator-activated receptor signaling pathway.Journal of diabetes investigation · 2016Article
- Peroxisome Proliferator-Activated Receptor Modulation during Metabolic Diseases and Cancers: Master and Minions.PPAR research · 2016Review
- Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions.PPAR research · 2015Review
- White adipose tissue reference network: a knowledge resource for exploring health-relevant relations.Genes & nutrition · 2015Article
- Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review.Nutrition journal · 2014Review
- Taking diabetes to heart--deregulation of myocardial lipid metabolism in diabetic cardiomyopathy.Journal of the American Heart Association · 2013Review
- Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.Current osteoporosis reports · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peroxisome proliferator-activated receptors (PPARs) play an important role in regulating both glucose and lipid metabolism. Agonists for both PPARgamma and PPARgamma have been used to treat dyslipidemia and hyperglycemia, respectively. In addition to affecting glucose metabolism, PPARgamma agonists also regulate lipid metabolism. In this review, we will focus on the randomized clinical trials that directly compared the lipid effects of the thiazolidinedione class of PPARgamma agonists, pioglitazone and rosiglitazone, head-to-head either as monotherapy or in combination with other lipid-altering or glucose-lowering agents.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.